National study testing drug to treat graft-versus-host disease after stem cell transplants
University of Nebraska Medical Center (UNMC)University of Nebraska Medical Center leading national team to determine if ruxolitinib is effective for treating a certain type of graft versus host disease (GVHD) called sclerotic. The grant is funded by Incyte, a global biopharmaceutical company.